SAN FRANCISCO, Aug. 31, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the quarter ended June 30, 2016 and provided an update on the company's recent achievements and upcoming events.
"Audentes has accomplished a number of significant milestones in 2016, culminating in the successful completion of our initial public offering," stated Matthew R. Patterson, President and Chief Executive Officer. "The IPO has not only added leading life sciences investors to our shareholder base, but has provided the financial resources to rapidly advance our pipeline of innovative therapies into clinical development. We have also recently completed the build-out of our state-of-the-art manufacturing facility, and expect to commence cGMP production runs in the fourth quarter of this year."
Mr. Patterson continued, "We plan to file investigational new drug applications for three of our development programs by the first quarter of 2017, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome and AT982 for the treatment of Pompe disease. We expect to report preliminary data from all three programs in the second half of 2017."
Last updated on: 31/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.